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Background
Dendritic cells (DC) are gatekeepers of immunity, criti-
cal to both an initiate immune response upon infection
and promote tolerance to self-antigens.
Methods
We have just established that DC subsets in the skin that
constitutively migrate into LNs can individually and col-
lectively temper an on-going immune response. Tissue
DC originating in skin share a unique transcriptome signa-
ture geared towards immune dampening when compared
to their lymphoid counterparts in both mouse and human.
Results
Here we demonstrate expression of unique core skin DC
transcripts are closely associated with increased clinical
aggressiveness of BCC in humans and the stratify stage
4 melanoma outcomes. In mice, loss of signature genes in
DC, which include but are not limited to PD-L1/PD-L2,
lead to enhanced antigen-specific immunity, decreased
tumor growth, and improved anti-tumor vaccine priming
to melanoma skin cancer by distinguishable molecular
control of T cell effector function and clonal proliferation.
Conclusions
These data suggest core skin DC signatures regulate the
immune-epithelial interface.
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